A Phase 2 interventional study of OrthoDerm transdermal nitroglycerin patch in Tendonitis, sponsored by Cure Therapeutics. Status unknown at 1 site in Poland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2007-03-15.
Sponsored by Cure Therapeutics · Phase 2, Interventional, and Treatment
The purpose of the study is to evaluate the effectiveness and safety of the use of low-dose nitroglycerin transdermal patches to treat pain and function in chronic tennis elbow.
Chronic tendonitis remains difficult to treat. Nitric oxide has been demonstrated to stimulate tenocytes to proliferate, differentiate and produce matrix components including collagen. Studies have demonstrated that nitroglycerin transdermal patches, which release nitric oxide, reduce pain and increase function in patients with chronic tendonitis. The purpose of the present study is to examine the efficacy of three dose levels of nitroglycerin, compared to placebo, in reducing pain and increasing function in patients with chronic (greater than three months' duration) lateral epicondylitis.
413 studies on the registry are indexed under Tendinopathy; 64 are open to participants now.
This study's enrollment of 164 is above the median of 50 across 339 interventional studies indexed under Tendinopathy.
Browse Tendinopathy studies →This is the only study on the registry with Cure Therapeutics as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
pain-free grip strength
pain at rest
pain on provocation
function
This study is status unknown, as verified in Mar 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.